Recent developments in plasma biomarkers, particularly phosphorylated tau protein 217 (pTau217), offer practical in vivo measures of AD pathology and are strongly associated with amyloid and tau PET tracer uptake.30 The gene discussed is MAPT; the disease is Alzheimer disease.